Abstract-We previously demonstrated that the neuronal expression of calcltomn gene-related peptlde (CGRP), a potent vasodllator, IS Increased m deoxycortlcosterone-salt-induced hypertension where it acts as a compensatory vasodllator to attenuate the elevated blood pressure To determine whether CGRP IS playing a similar role m subtotal nephrectomysalt-induced hypertension, hypertension was Induced m Sprague-Dawley rat? (n=6) by subtotal nephrectomy and 1 0% saline drmkmg water Control rats (n=6) wete sham operated and given tap water to drmk CGRP,,-,,,, a CGRP receptor antagonist, was used to assess the hemodynamlc iole of CGRP m this setting CGRP mRNA and peptlde levels m dorsal root ganglia were also determined Three weeks after either protocol, all rats had intravenous (for drug admmlstratlon) and arterial (for contmuous mean arterial pressure momtormg) catheters surgically placed and were studied m the conscious, unrestrained state CGRP,,_,,, (3 2 or 6 4X 10" pmol/L m 0 1 mL saline) and vehicle were administered mtravenously to all rats Baseline mean arterial pressure was higher m the subtotal nephrectomlzed rats compared with the controls (17325 versus 11325 mm Hg, P< 002) Vehicle admmlstratlon did not change rnean arterial pressure m either group, and CGRP,,-,,, admmlstratron did not alter mean arterial pressure m the nolmotenslve group In contrast, CGRP,,-,,, admmlstratlon to the subtotal nephrectomlzed rats rapidly increased the already elevated mean arterial pressure at both the 3 2X104 pmol/L dose (7 8+1 1 mm Hg, P< 05) and the 6 4X10" pmol/L dose (Y 620 8 mm Hg, P< 01) CGRP mRNA and peptlde levels m the dorsal root gangha were not significantly different between the two groups These data suggest that m subtotal nephrectomy-salt-Induced hypertension, CGRP may play a compensatory depressor role m an attempt to lower the elevated blood pressure (Hy2lertension.
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Key Words: calcltomn gene-related peptlde n blood pressure n hypertension, expermlental H neuropeptldes n genes n RNA C alcltomn gene-related peptlde (CGRP) 15 a 37-ammo-acid neuropephde that IS widely mstnbuted in the central and peripheral nervous systems m mammals ' CGRP IF denved from the tissue-specific alternative sphcmg of the primary transcript of the calcltonm/CGRP gene and IS produced almost exclusively m neuronal @sues ' ' A promment site of CGRP synthens 1s the dorsal root ganglia (DRG), which contain the cell bodes of tierent sensory nerves that termmate penpherally on blood vessels and other tissues Innervated by the tensory nervous system and centrally m lanunae I/II of the dorsal horn of the spinal cord ' Immunoreactlve CGRP (ICGRP)-contannng nerve fibers are uldely dlstnbuted In the cardovascular system In blood vessels these nerves are found at the Junction of the advenhtla and the me&a passing Into the muscle layer ' 4 In these nerve fibers, CGRP 1s often colocahzed with substance I' and other tachykmuls 5
In VIVO and m vitro studies have demonstrated that CGRP IS a very potent vasodllator, approxunately 100 to 1000 times more potent than other vasodllators such as adenosme, substance P, or acetylcholme '-" CGRP has been shown to dilate multiple vascular beds, with the coronary vasculature bemg a particularly sensltlve target '),I" Systemic admmlstratlon of CGRP decreases blood pressure m a dose-dependent manner In normotenslvc anunals and humans and m the spontaneously hypertensive rat (SHR) '," The primary mechamsm responslble for this reduction In blood pressure IS peripheral arterial dllatlon ","' These findmgs suggest that CGRP may play a significant role m regulating peripheral vascular tone and regonal organ blood flow, both under normal physlologcal condmons and m the pathophyslology of hypertension We previously reported that during the onset phase of deoxycortlcosterone-salt (DOC-salt)-Induced hypertension In the rat, CGRP mRNA accumulation was significantly mcreased m DRG, and, correspondmgly, ICGRP levels were markedly elevated In lammae I/II of the spmal cord compared with that of normotenslve controls ' We later showed that intravenous admnustratlon of the specific CGRP receptor antagomst CGRP,,,, produced slgmficant increases m the already elevated mean arterial pressure (MAP) m the DOC-salt hypertensive rats but not m the controls '" These data suggest that the Increase m CGRP expression m the DRG IS a compensatory vasodllator mechanism to attenuate the elevated blood pressure This finding IS m agreement with an earlier study mvolvmg hypertensive humans that showed an Increase 392 CGRP Arlington Heights, IL) After the hemodynanuc stuches, the rats were deeply anesthetized by infusion of ketamme and xylazme (100 and 5 mg/kg) through the Jugular vem catheter The rats were then killed by decapltatlon and the cervical, thoraclc, and lumbar DRG from each ammal were lmmech- In SN rats (n=6) on 1% saline and sham-operated rats (n=6) that were provided tap water to drink Blood pressure determinations were done just before the surgical procedures (day 0) and on the indicated days thereafter The values are reported as the mean?zSEM *P< 05, '*PC 01, SN-rats vs controls on each day ately dissected and frozen m liquid nitrogen For each ammal, the DRG on one side of the spinal cord were separated from those on the other side of the cord such that half of the DRG were used for CGRP mRNA analysis and the other half for CGRP peptide quantification To determme relative CGRP mRNA levels, total cellular RNA was isolated from the DRG by the guamdine-isothiocyanate method I4 The RNA samples were subJected to electrophoresis on denaturing formaldehyde-agarose gels 's The fractionated RNAs were transferred to nylon membranes and hybnchzed with the "P-labeled CGRP DNA probe As a control, the CGRP probe was removed from the membrane which was then hybnchzed with the 18s rDNA probe After hybndrzatlon, ehe membranes were washed and exposed to Kodak X-Omat sham-operated (n=6) rats that received tap water to drink remained normotensive. On days 18 to 20 after the initiation of each protocol, rats had arterial (for continuous MAP recording) and intravenous (for drug administration) catheters surgically implanted and were studied in a fully awake and unrestrained state. Baseline MAP was markedly higher in the SN-hypertensive rats compared with the controls (173t-5 versus 113+-5 mm Hg, IK.001). Administration of saline (0.1 mL IV) did not significantly change MAP in either group (SN rats 2.020.9 versus controls 2.8t0.5 mm Hg). Likewise, as shown in Fig 2, the effects of bolus intravenous administration of two different doses of CGRP,,,,, (3.2X104 or 6.4X10" pmol/L in 0.1 mL) on MAP in the control group were similar to those observed with saline alone, which did not significantly alter the blood pressure. In contrast, the infusion of CGRPc8-j,J to the SN-hypertensive rats rapidly (the MAP increase began approximately 15 to 20 seconds after antagonist administration) produced a further increase of the already elevated MAP at both the lower (7.821.1 mmHg, K.05) and higher (9.62-0.8 mm Hg, P<.Ol) doses. The pressor activity of CGRP,,,,, was relatively short-lived, lasting approximately 60 seconds for the lower dose and 90 seconds for the higher dose. The values shown in this figure represent the peak responses, which lasted approximately 8 seconds and 15 seconds for the lower and higher doses, respectively. This transient effect of CGRP,,-,,, has been observed by us and other investigators who have used this antagonist for in vivo hemodynamic studies and most likely reflects the rapid proteolysis of this peptide in the circulation.'r'~'"~'7 As part of these experiments, we also measured heart rate, which was not significantly changed by the CGRP antagonist in either of the groups. These results suggest that in SN-induced hypertension, CGRP is playing a ,I 2 3 4 5,,6 7 8 9 10, Control SN Figure  3 . Northern blot analysis of RNA samples from the SNhypertensive and control rats. Total cellular RNA samples isolated from DRG were fractionated on a denaturing formaldehyde-agarose gel and transferred to a nylon membrane. The membrane was hybridized with the3'P-labeled CGRP genomic DNA insert (top). The CGRP probe was removed from the membrane which was subsequently hybridized with the 32P-labeled 1% rDNA probe (bottom).
After hybndlzation with each probe the membrane was washed and exposed to x-ray film at -70°C with an intensifying screen.
compensatory depressor role to mmimlze the blood pressure increase.
Analysis of CGRP mRNA and iCGRP Content in DRG from SN-Hypertensive and Control Rats To determine whether neuronal CGRP expression was enhanced m the SN-qalt hypertensive rats, CGRP mRNA and 1CGRP levels were quantified m the DRG taken from the ratv used in the hemodynamlc experunent4 de5cnbed above. Fig 3  is a representative Northern blot demonstrating the levels of both the 1.2-kb CGRP mRNA specie? (a-and P-CGRP) and 18s rRNA present in the DRG RNA samples. Scannmg laser densltometrlc analy$ls of the autoradlographs was then performed to quantify the hybridlzatlon Tlgnal? for CGRP mRNA and 18s rRNA. When the value? for CGRP mRNA levels were normalized to those for 18s I-RNA to control for possible differences m loadmg of the RNA samples between the groups, there were no detectable differences In DRG CGRP mRNA content between the SN-hypertenclve and A CGRP-specific radlolmmunoassay was then used to determine 1CGRP levels m the DRG from the two groups of rats The results from this expenment were consistent with those from the RNA analysis and showed no significant differences m DRG 1CGRP content between the two groups (SN-hypertensive 0 62?0 04 versus control 0 6750 08 pg lCGRP/Fg total protein) These data indicate that the deprescar effect of CGRP observed m the SN-hypertensive rats does not result from the enhanced neuronal (DRG) expression of CGRP, as seen m the DOC-salt model, but 1s instead mediated through an unidentified mechanism Discussion These results demonstrate that the infusion of a potent and specific CGRP receptor antagonist increased further the elevated blood pressure m SN-hypertensive rats but did not produce a detectable effect m the normotenslve control rats This action of CGRP,,-,,, 1s not simply the result of salt loading, because we previously reported that m sham-operated rats on 1% salme, when compared with sham-operated rats that received tap water, there was no change m the blood pressure during the 3-week treatment penod and the pressor effect of CGRP,,-,,, was not observed I0 These data are consistent with the hypothesis that m this model of experimental hypertension, CGRP 1s acting as a compensatory depressor m an attempt to counteract the blood pressure increase This interpretation must be qualified by the fact that we have not yet determined whether the pressor effect of CGRP receptor blockade would be dlmmlshed m a time-dependent manner If the blood pressure was phamlacologlcally normalized m these animals We cannot rule out the posslblhty that the effect of CGRP on blood pressure 1s secondary to some other effect engendered by the SN We do not think this 1s likely, because we demonstrated m earlier studies with the DOC-salt hypertensive rats that control animals which underwent a unmephrectomy, with or without saline-drinking water, did not exhibit a pressor response after admmlstratlon of the CGRP receptor antagonist "I In light of this caveat, the present findings are consistent with those that we previously reported m DOC-salt hypertemive rats'" and m N"-mtro-L-argmme methyl ester (L-NAME)-induced hypertension durmg pregnancy " The magnitude and duration of the hypertensive effect of CGRP,,-,,, was quite similar m all three models The mablhty of CGRP,,_,,, to alter blood pressure m the control rats implies that CGRP does not partlclpate m the regulation of systemic blood pressure m the normotenslve state but does not rule out a role for CGRP m the modulation of regonal organ blood flow under normal physmloglcal condmons It has been well documented that CGRP participates m the regulation of regional organ blood flow m the gut," and it has been reported that m studies m which CGRP,,,,, was used m normal rats, CGRP was responsible for approximately 30% of basal coronary blood flow "
Our data suggest that there may be two different mechanisms by which CGRP exerts Its compensatory vasodllator effect During the onset phase (4 weeks) of DOC-salt hyptrtension, we observed a severalfold increase m CGRP mR@iA accumulation m the DRG and 1CGRP m the spinal cord when compared with the normotenslve controls Because CGRP,-,,, admmlstratlon produced an Increase m MAP only m the hypertensive rats, it seems that the enhancement of neuronal CGRP synthesis, and presumably release, 1s responsible for the observed depressor actlvlty of this neuropeptlde
In the present study, and m our earlier expenments with the hypertensive pregnant rats, endogenous CGRP was also shown to play a counterregulatory role, however, CGRP expresslon m the DRG wac not slgmficantly altered m these hypertensive rats when compared with the normotenslve controls It should be noted, however, that we cannot completely rule out a small but real change m DRG CGRP expression between the SN-hypertemlve and normotenslve groups Based on our previous studies, both m VIVO~)'~~' and m vltro,22-'4 it 1s unlikely that any change m CGRP expression <I 5-fold would be statlstlcally slgmficant gven the number of animals m each group If there was, m fact, no change m CGRP m the hypertensive rats, then one possible mechanism to explain the depressor effect of CGRP 1s an increased vascular responslveness to this peptlde Although there are supporting data demonstrating an altered vascular sensltlvlty to CGRP m one model of hypertenslon,2i our current data do not permit further speculation along these lines
Our results also agree with the findings of Kohlmann et al," who showed that the acute mhlbltlon of the substance P receptor (NK-1) increased blood pressure m the salt-dependent DOC-salt and SN models of hypertension Substance P 1s colocahzed with CGRP m many penvascular sensory nerve fibers, and the release of these two neuropeptldes 1s regulated by many of the same factors " These mvestlgators also demonstrated a similar action of the substance P antagonist m the salt-dependent 1 kidney-1 clrp model but not the salt-mdependent 2 kidney-1 clip rats With regard to CGRP, we are unable to comment on these latter two models of hypertension because we are not aware of any studies on the hemodynamlc actions of CGRP (,,,, or whether there are any alterations m neuronal CGRP expression m these settings Taken together, these data suggest that m the DOC-salt and SN-hypertensive rats, both CGRP and substance P are acting as compensatory vasodllators m response to the increase m blood pressure With regard to the depressor role of substance P m these two models, it IS not known whether there are any significant changes m the expression or vascular sensltlvlty to this tachykmm Kohlmann et alI2 also demonstrated that the substance P receptor antagonist did not increase MAP m the SHR, and other mvestlgators have shown that there 1s a decrease m the clrculatmg levels of Fubstance P m this genetic, salt-mdependent model of hypertension 2h We have also reported that m the SHR there was a slgmficant decrease m CGRP mRNA accumulation m the DRG and a reduction m 1CGRP content m the spinal cord m comparison to Wlstar-Kyoto control rats 2' " Preliminary studies using CGRP,,_,,,, conducted m our laboratory, also showed that endogenous CGRP does not play a depressor role m the SHR (unpublished observations) Therefore, it 1s possible that m SHR, a decrease m vasodllator activity caused by the downregulatlon of CGRP (and sub-stance P) could contribute to the development and mamtenance of the high blood pressure Although it 1s not unexpected that at least m some models of expenmental hypertension there 1s a compensatory depressor response to the elevated blood pressure, there 1s accumulatmg evidence that perlvascular sensory nerve fibers are involved m this antlhypertenslve mechamsm(s) In this study as well as our previous experiments using the DOC-salt model and L-NAME-treated pregnant rats, gven the rapid onset (15 to 20 seconds) of the hypertensive effect of CGRP,,-,,, and because the antagonist probably does not penetrate the central nervous system, it 1s likely that most of the pressor activity of CGRP,,-,,, seen m these studies results from a direct mteractlon of the antagonist wth peripheral vascular CGRP receptors (probably CGRP receptor type I) Support for thn conclusion 1s provided by radlohgand bmdmg and functlonal studies which showed that CGRP,s_,,, 1s a competltlve mhlbltor of CGRP bmdmg and that the type I CGRP receptor displays the highest sensltlvq to this antagonist '*x" This receptor subtype has been shown to be the predominant CGRP receptor present m the heart and penpheral blood vessels 293" In addition, it IS well documented that the CGRP,,,, can mhlblt the vasodllator and hypotenslve effects evoked by exogenously administered or endogenously released CGRP m vlvo '",'6-'8~3i Other studies suggest that it 1s the capsalcm-sensltlve class of sensory neurons that participates m this anahypertenslve response The neurotoxm capsalcm, when administered neonatally, results m a selective destructlon of a large subpopulatlon of small diameter, mainly unmyehnated CGRP (and substance P)-contammg pmmary afferents 32 It has been shown that the induction of DOC-salt hypertension m capsalcm-pretreated and control rats resulted m an increase m blood pressure that was more rapid m onset and of greater magnitude m the capsalcm-pretreated animals 33 These same animals also received intravenous admmlstratlon of capsalcm which produces a massive acute release of CGRP and substance P In these expenments, the systemic admmlstratlon of this neurotoxm produced a much larger hypotenslve effect m the hypertensive control animals when compared with those that had received neonatal capsalcm Therefore, the ablation of a slgmficant number of CGRP (and substance P)-producing sensory neurons seems to markedly attenuate the sensory neuropeptldemediated depressor response and exacerbates the development of hypertension m the DOC-salt rat Taken together, results from these multiple studies strongly support the hypothesis that afferent neurons, whose primary function 1s the transmlsslon of sensory mformatlon from penpheral tissues to the spinal cord, can also regulate vascular tone and regional organ blood flows through the efferent release of neuropeptldes (CGRP, substance P) from primary afferent nerve termmals ' ' 34 35 Numerous studies performed m vlvo and m vitro using either sensory nerve preparations or pnmary cultures of DRG neurons have shown that local factors such as nerve growth factor,3" vascular wall tenslon,5'34 bradykmm/prostaglandms,37 endothehn," as well as mteractlons with the sympathetic nervous system'" can modulate the release of CGRP and substance P Moreover, using primary cultures of adult rat DRG neurons we have demonstrated that nerve growth factor2' or bradykmm/prostaglandmsz3
can upregulate CGRP synthesis and release, whereas glucocortlcolds** or a*-adlenoreceptor agonlsts24 can attenuate the stlmulatory effects of nerve growth factor on CGRP Therefore, alterations m these factors, some of which are known to occur m hypertension, may mediate any changes seen m neuronal CGRP expressmn and release Furthermore, m certain hypertensive states, changes m as yet umdentlfied factors could alter the sensltlvlty of the vasculature to CGRP (and substance P) Thus, vascular tone may be modulated by changes m the expression and release of CGRP and/or by alterations m vascular responsxveness to this neuropeptlde In summary, the results presented herem suggest that m SN-mduced hypertension CGRP 1s playing a compensatory depressor role to partially counteract the increase m blood pressure m the absence of any detectable change m CGRP expression m the DRG Although it 1s tempting to speculate that the mechanism of this effect 1s through an increase m the vascular responsiveness to CGRP, further studies are necessary to evaluate this posslblhty These St&es, together with those usmg the DOC-salt and SHR models, are also consistent with the hypothesis that the ability of CGRP (and substance P) to partially counteract the Increased blood pressure IS strongly influenced by the salt-dependence of the hypertensive state The mechanism(s) of this phenomenon 1s not known However, our studies with the nonsalt-dependent hypertensive L-NAME-treated pregnant rats suggest that other factors may influence the antlhypertenslve actions of these vasodllator neuropeptldes 
